Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies

NCT02118584 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02118584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02118584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
September 15, 2014
Completion date
October 5, 2023
Enrollment
1,822 (actual)
Sites
411

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis